Drug Profile
Zilovertamab vedotin - VelosBio
Alternative Names: MK 2140; VLS 101Latest Information Update: 28 Jan 2024
Price :
$50
*
At a glance
- Originator VelosBio
- Class Antineoplastics; Auristatins; Drug conjugates; Immunoconjugates; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Apoptosis stimulants; Cell cycle inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II/III Diffuse large B cell lymphoma
- Phase II Bladder cancer; Breast cancer; Chronic lymphocytic leukaemia; Follicular lymphoma; Gastric cancer; Haematological malignancies; Mantle-cell lymphoma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Richter's syndrome; Solid tumours
- Preclinical Ewing's sarcoma; Precursor B-cell lymphoblastic leukaemia-lymphoma
Most Recent Events
- 28 Jan 2024 No recent reports of development identified for preclinical development in Richter's-syndrome in USA (IV)
- 28 Jan 2024 No recent reports of development identified for preclinical development in Richter's-syndrome in USA (SC)
- 09 Dec 2023 Updated efficacy and adverse event data from a phase II waveLINE-004 trial in Diffuse large B cell lymphoma presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-2023)